• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
University of Calgary - Developmental Therapeutics Review - Q1 2011 Product Image

University of Calgary - Developmental Therapeutics Review - Q1 2011

  • ID: 1589989
  • March 2011
  • 42 pages
  • Global Markets Direct

University of Calgary – Developmental Therapeutics Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “University of Calgary – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by University of Calgary.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of University of Calgary with complete description READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
University of Calgary Snapshot
University of Calgary Overview
Key Information
Key Facts
University of Calgary – Research and Development Overview
Key Therapeutic Areas
University of Calgary – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
University of Calgary – Pipeline Products Glance
University of Calgary – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
University of Calgary Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
University of Calgary – Drug Profiles
25% Dextrose + 1% Lidocaine
Product Description
Mechanism of Action
R&D Progress
Aspirin + Clopidogrel + Simvastatin
Product Description
Mechanism of Action
R&D Progress
Atorvastatin
Product Description
Mechanism of Action
R&D Progress
Atorvastatin + Niaspan
Product Description
Mechanism of Action
R&D Progress
Indomethacin
Product Description
Mechanism of Action
R&D Progress
Leflunomide + Sirolimus
Product Description
Mechanism of Action
R&D Progress
Minocycline
Product Description
Mechanism of Action
R&D Progress
Phase II - Trial Details
Phase III - Trial Details
Nabilone
Product Description
Mechanism of Action
R&D Progress
Frovatriptan
Product Description
Mechanism of Action
R&D Progress
Gamunex
Product Description
Mechanism of Action
R&D Progress
Human Recombinant Erythropoietin
Product Description
Mechanism of Action
R&D Progress
Intravenous immunoglobulin + Normal Saline
Product Description
Mechanism of Action
R&D Progress
Intravenous immunoglobulin + Normal Saline
Product Description
Mechanism of Action
R&D Progress
MCN36
Product Description
Mechanism of Action
R&D Progress
Simvastatin
Product Description
Mechanism of Action
R&D Progress
Tissue Plasminogen Activator
Product Description
Mechanism of Action
R&D Progress
University of Calgary – Pipeline Analysis
University of Calgary – Pipeline Products by Therapeutic Class
University of Calgary - Pipeline Products By Target
University of Calgary – Pipeline Products by Route of Administration
University of Calgary – Pipeline Products by Molecule Type
University of Calgary - Dormant Projects
University of Calgary – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos